Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia. Hangzhou, Zhejiang, China, July 3, 2024, Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that the company has completed the enrollment in the Phase 1b/2a trial evaluating DR10624 in obese subjects with modest hypertriglyceridemia in New Zealand. DR10624 is a first-in-class (FIC), long-acting tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR). The Phase 1b/2a study is a randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DR10624 in adult obese subjects (BMI of 30 to 45 kg/m2) with modest hypertriglyceridemia (fasting triglyceride ≥150 mg/dL (1.7 mmol/L), and <500 mg/dL (5.7 mmol/L), at screening). The study evaluates DR10624 treatment across four different dose levels. The participants will receive once-weekly subcutaneous injection of DR10624 or placebo (in a 10:2 ratio) for 12 weeks. The study will also evaluate the effects of DR10624 on serum lipids, liver fat, and body weight. Dr.Yanshan Huang Founder ＆ CEO of Doer Bio "DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonizing FGF21R, GLP-1R, and GCGR. Utilizing Doer Bio’s proprietary MultipleBody® platform technology, DR10624 is designed and engineered to exhibit balanced activity for various metabolic diseases. In our preclinical studies, DR10624 has shown outstanding potency on body weight reduction, blood lipid normalization, and liver function improvement.” said Yanshan Huang, Ph.D., founder and Chief Executive Officer of Doer Bio. Dr.Yongliang Fang COO of Doer Bio “We're excited to announce the successful completion of patient enrollment for our Phase 1b/2a clinical trial of DR10624 in New Zealand. This achievement marks an important milestone in our clinical translation of DR10624 globally. We anticipate reporting the trial results in early 2025. There is a growing unmet medical need for patients suffering from obesity and hypertriglyceridemia. We look forward to developing DR10624 as a potential treatment for patients struggling with metabolic dysfunction.” commented Yongliang Fang, Ph.D., Chief Operating Officer of Doer Bio. More information about the Phase 1b/2a clinical trial is available at clinicaltrials.gov (NCT05378893) About Doer Bio Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”) is a clinical stage biopharmaceutical company that focuses on the discovery and development of multi-domain based multi-specific biotherapeutics to address unmet medical need in the field of metabolic diseases and cancers. Doer Bio has developed multiple proprietary platform technologies, including xLONGylation®, MultiBody®, AccuBody®, and SMART-VHHBody. For more information about Doer Bio, please visit www.doerbio.com.
全球首创3靶点激动剂DR10624用于肥胖合并高甘油三酯血症的1b/2a期临床试验完成全部受试者入组
<END>
*版权声明：本网站所转载的文章，均来自互联网，旨在传递更多信息。鉴于互联网的开放性和文章创作的复杂性，我们无法保证所转载的所有文章均已获得原作者的明确授权。如果您是原作者或拥有相关权益，请与我们联系，我们将立即删除未经授权的文章。本网站转载文章仅为方便读者查阅和了解相关信息，并不代表我们认同其观点和内容。读者应自行判断和鉴别转载文章的真实性、合法性和有效性。
相关资讯
- 综合
减肥药不行了，诺和诺德靠AI，还有没有搞头？
GMP行业药文
2026-05-27
《自然》子刊：从蟒蛇身上，科学家找到了减肥的新灵感
学术经纬
2026-03-25
Cell Metab | 新型催乳素释放肽类似物NN501减肥机制与疗效
BioArtMED
2026-01-04
两篇NEJM齐发：司美格鲁肽复方制剂创造减肥新纪录，反超替尔泊肽
药时空
2025-06-24
IF=14.3|脂肪分解的“开关”——AMP或成为改善肥胖的关键靶点
汉恒生物
2025-06-24
云顶新耀新型BTK抑制剂EVER001的1b/2a期临床试验积极结果首次亮相第62届欧洲肾脏协会大会
云顶新耀
2025-06-09
中国抗体与云顶新耀授权合作获进展，新型BTK抑制剂SN1011在1b/2a期临床试验阶段性数据中取得积极结果
SINOMAB 中抗集团
2024-12-04
打造肾病“三驾马车”！云顶新耀潜在“同类最佳”新一代肾病药物取得1b/2a期临床试验积极结果
凯莱英药闻
2024-12-04
针对肥胖症治疗！凯医药与礼来达成临床合作
Pharma CMC
2024-11-21
来凯医药与礼来在美国就LAE102针对肥胖治疗达成合作
Medaverse
2024-11-20
共发布文章：13篇
最新发布文章
- 道尔生物DR10624治疗重度高甘油三酯血症的两项三期临床研究完成首例患者入组
- EASL 2026 | 道尔生物公布DR10624在重度高甘油三酯血症II期临床研究中对肝脏脂肪及改善肝脏代谢指标的研究结果
- AACR 2026｜道尔生物DR319-DP双抗双载荷ADC亮相，突破实体瘤疗效与耐药性瓶颈
- AACR 2026 | 道尔生物展示双抗双载荷ADC临床前数据
- 道尔生物DR10624重度高甘油三酯血症美国IND获FDA批准
- 道尔生物基于Accubody®技术平台构建的EGFR T-cell engager前药项目亮相ESMO 2025大会
- 道尔生物COO方永亮博士入选浙江省卓越工程师
- 道尔生物宣布完成DR30206联合标准化疗用于治疗晚期或转移性消化道肿瘤患者的Ib/ IIa期临床试验首例受试者给药
全球药物研发中心
全球研发数据与行业前沿情报
395,503个
全球在研药物数
7,008个
本月临床试验数
研发动态
相关报告
政策法规
-
2026-10-28
-
2026-10-28
-
2026-10-28
-
摩熵咨询 33 54
-
摩熵咨询 20 3
-
摩熵咨询 20 10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
-
颁布机构：国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构：国家药品监督管理局 2026-09-10
最新资讯
- 步长制药AGT小核酸BC923及PD-1/TIGIT双抗BC008-1A同日获批临床，剑指高血压与复发性脑胶质瘤
- 摩熵数科荣获2026年成都市企业技术中心认定！数据+AI双引擎赋能生命科学产业升级
- 先声药业合作品种玛氘诺沙韦上市失利，国产流感创新药竞争格局再迎变局
- 恒瑞医药三季报炸场：归母净利暴增88.92%，创新药持续增长，ADC瑞康曲妥珠单抗第5项适应症获受理
- 诺诚健华Q3营收大增150.60%：BD里程碑收入推高业绩，奥布替尼独挑商业化大梁
- 2026年第43周10.19-10.25全球创新药研发概览
- 2026年第43周10.19-10.25国内医药大健康行业政策法规汇总
- 2026年第43周10.19-10.25国内仿制药/生物类似物申报/审批数据分析
GCGR
当前排名
第374名
6.45分
摩熵指数
1个
新获批上市药物
摩熵指数榜单TOP5
靶点
企业
-
CD19100 -
CD391.57 -
KRAS87.52 -
EGFR77.53 -
PSMA76.5
-
江苏恒瑞医药股份有限公司99.5
-
华润医药集团有限公司98.17
-
正大天晴药业集团股份有限公司97.28
-
上海复星医药（集团）股份有限公司96.32
-
石药控股集团有限公司95.68
添加收藏
新建收藏夹
取消
确认
对不起，您今日剩余下载额度不足，请明日再来！
返回
对不起！您还未登录！请登录后查看
收藏
登录后参与评论
暂无评论